Skip to main content
. 2022 Nov 10;270(2):1076–1094. doi: 10.1007/s00415-022-11478-0

Fig. 4.

Fig. 4

Decision curve analysis of net benefit of the incident neuropathic pain model in GoDARTS. Imputed dataset 59 was randomly chosen to represent clinical utility and the net benefit at outcome incidence (10.7%) was 0.020